BR9911324A - Therapeutic combinations of estrogen receptor (selective) modulators (serm) and growth hormone secretagogues (ghs) for the treatment of musculoskeletal fragility - Google Patents

Therapeutic combinations of estrogen receptor (selective) modulators (serm) and growth hormone secretagogues (ghs) for the treatment of musculoskeletal fragility

Info

Publication number
BR9911324A
BR9911324A BR9911324-4A BR9911324A BR9911324A BR 9911324 A BR9911324 A BR 9911324A BR 9911324 A BR9911324 A BR 9911324A BR 9911324 A BR9911324 A BR 9911324A
Authority
BR
Brazil
Prior art keywords
fragility
compositions
ghs
serm
modulators
Prior art date
Application number
BR9911324-4A
Other languages
Portuguese (pt)
Inventor
Hua Zhu Ke
Mei Li
Lydia Codetta Pan
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR9911324A publication Critical patent/BR9911324A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Patente de Invenção: <B>''COMBINAçõES TERAPêUTICAS DE MODULADORES DE RECEPTOR (SELETIVO) DE ESTROGêNIO (SERM) E SECRETAGOGOS DE HORMÈNIO DO CRESCIMENTO (GHS) PARA O TRATAMENTO DE FRAGILIDADE MúSCULO-ESQUELETAL''<D>. Esta invenção refere-se a composições de combinações farmacêuticas e a métodos que contenham (-)-cis-6-fenil-5-(4-(2-pirrolidin-1-il-etóxi)-fenil)-5,6,7,8-tetra-hidronaftale n-2-ol ou um sal farmaceuticamente aceitável dos mesmos e 2-amino-N-(2-(3a(R)-benzil-2-metil-3-oxo-2,3,3a,4,6,7-hexahidro-pira zolo-[4,3-c]piridin-5-il)-1-(R)-benziloximetil-2-oxo-etil)-iso-butiramida ou um sal farmaceuticamente aceitável da mesma, métodos para a utilização de tais composições e kits que contenham tais composições. As composições são úteis para o tratamento de fragilidade músculo-esqueletal, incluindo a osteoporose, a fratura osteoporótica, a fraca massa óssea, a fragilidade e a fraca massa muscular.Invention Patent: <B> '' THERAPEUTIC COMBINATIONS OF ESTROGEN RECEIVER (SELECTIVE) MODULATORS (SERM) AND GROWTH HORMONE (GHS) SECRETAGOGUES FOR TREATING MUSCLE-SKELETAL FRAGILITY '' <D>. This invention relates to pharmaceutical combination compositions and methods containing (-) - cis-6-phenyl-5- (4- (2-pyrrolidin-1-yl-ethoxy) -phenyl) -5,6,7 , 8-tetrahydronaftale n-2-ol or a pharmaceutically acceptable salt thereof and 2-amino-N- (2- (3a (R) -benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyro zolo- [4,3-c] pyridin-5-yl) -1- (R) -benzyloxymethyl-2-oxo-ethyl) -iso-butyramide or a pharmaceutically acceptable salt thereof , methods for using such compositions and kits containing such compositions. The compositions are useful for the treatment of musculoskeletal fragility, including osteoporosis, osteoporotic fracture, weak bone mass, fragility and weak muscle mass.

BR9911324-4A 1998-06-16 1999-06-16 Therapeutic combinations of estrogen receptor (selective) modulators (serm) and growth hormone secretagogues (ghs) for the treatment of musculoskeletal fragility BR9911324A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8946998P 1998-06-16 1998-06-16
PCT/IB1999/001117 WO1999065486A1 (en) 1998-06-16 1999-06-16 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty

Publications (1)

Publication Number Publication Date
BR9911324A true BR9911324A (en) 2001-04-03

Family

ID=22217825

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911324-4A BR9911324A (en) 1998-06-16 1999-06-16 Therapeutic combinations of estrogen receptor (selective) modulators (serm) and growth hormone secretagogues (ghs) for the treatment of musculoskeletal fragility

Country Status (30)

Country Link
EP (1) EP1087764A1 (en)
JP (1) JP2002518326A (en)
KR (1) KR20010052852A (en)
CN (1) CN1301160A (en)
AP (1) AP9901582A0 (en)
AR (1) AR018869A1 (en)
AU (1) AU4054799A (en)
BG (1) BG105041A (en)
BR (1) BR9911324A (en)
CA (1) CA2335134A1 (en)
CO (1) CO5070587A1 (en)
EA (1) EA200001186A1 (en)
GT (1) GT199900087A (en)
HN (1) HN1999000097A (en)
HR (1) HRP20000859A2 (en)
HU (1) HUP0102505A3 (en)
ID (1) ID27599A (en)
IL (1) IL138630A0 (en)
IS (1) IS5691A (en)
MA (1) MA26652A1 (en)
NO (1) NO20006312L (en)
OA (1) OA11505A (en)
PA (1) PA8475901A1 (en)
PE (1) PE20000646A1 (en)
PL (1) PL344981A1 (en)
SK (1) SK18912000A3 (en)
TN (1) TNSN99124A1 (en)
TR (1) TR200003544T2 (en)
WO (1) WO1999065486A1 (en)
ZA (1) ZA993975B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2653300A (en) * 1999-02-08 2000-08-29 Mcgill University Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding orphan nuclear receptor erralpha
EP1156120B1 (en) 2000-05-08 2006-11-22 Pfizer Products Inc. Enzymatic resolution of selective estrogen receptor modulators
BR0113626A (en) * 2000-08-30 2003-06-17 Pfizer Prod Inc Sustained-Release Formulations for Growth Hormone Secretors
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2006024931A2 (en) * 2004-08-31 2006-03-09 Pfizer Products Inc. Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator
CU23558A1 (en) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE
EP2644618B1 (en) 2007-02-09 2016-08-17 Ocera Therapeutics, Inc. tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (en) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (en) * 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS

Also Published As

Publication number Publication date
PE20000646A1 (en) 2000-08-05
BG105041A (en) 2001-08-31
ZA993975B (en) 2000-12-15
JP2002518326A (en) 2002-06-25
TNSN99124A1 (en) 2005-11-10
KR20010052852A (en) 2001-06-25
OA11505A (en) 2004-05-07
PA8475901A1 (en) 2000-05-24
PL344981A1 (en) 2001-11-19
HUP0102505A2 (en) 2001-11-28
IL138630A0 (en) 2001-10-31
HRP20000859A2 (en) 2001-04-30
CN1301160A (en) 2001-06-27
CO5070587A1 (en) 2001-08-28
GT199900087A (en) 2000-12-07
WO1999065486A1 (en) 1999-12-23
NO20006312D0 (en) 2000-12-12
EA200001186A1 (en) 2001-06-25
HUP0102505A3 (en) 2002-12-28
ID27599A (en) 2001-04-12
AR018869A1 (en) 2001-12-12
SK18912000A3 (en) 2001-10-08
HN1999000097A (en) 1999-11-03
IS5691A (en) 2000-10-27
CA2335134A1 (en) 1999-12-23
MA26652A1 (en) 2004-12-20
NO20006312L (en) 2000-12-12
EP1087764A1 (en) 2001-04-04
AU4054799A (en) 2000-01-05
AP9901582A0 (en) 1999-06-30
TR200003544T2 (en) 2001-04-20

Similar Documents

Publication Publication Date Title
YU18400A (en) Prostaglandin agonists and their use to treat bone disorders
BR9714155A (en) Prevention of bone mass loss and replacement by certain prostaglandin agonists.
EP0911321A3 (en) Compounds for the treatment of osteoporosis
BR0309875A (en) methods and compositions for treating peripheral nervous system disorders and novel compounds useful therefor
BR0100558A (en) Compositions and methods for treating osteoporosis
AP9801269A0 (en) Prostaglandin agonists.
BR9911324A (en) Therapeutic combinations of estrogen receptor (selective) modulators (serm) and growth hormone secretagogues (ghs) for the treatment of musculoskeletal fragility
BR9911228A (en) Therapeutic combinations comprising a selective modulator of an estrogen receptor and parathyroid hormone
BR9911357A (en) Therapeutic combinations of estrogen receptor (serm) (selective) modulators and growth hormone secretagogues (ghs) to treat musculoskeletal fragility
BR9908214A (en) Treatment for follicular lymphomas using lymphotoxin pathway inhibitors (lt)
WO2001080894A3 (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
BR9814403A (en) &#34;indole derivatives useful for the treatment, among others, of osteoporosis&#34;
BR9905974A (en) Derivatives of aryl carboxylic acid and tetrazole
IL124828A0 (en) Hyaluronic acid receptors binding agents and the use thereof
BR0206844A (en) Use of gal3 receptor antagonists for the treatment of depression and / or anxiety and compounds used in such methods.
CA2274381A1 (en) Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2
ECSP993020A (en) COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY
ECSP993021A (en) THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY
TH57984A3 (en) A therapeutic combination consisting of selective estrogen receptor modulators and parathyroid hormone.

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]